A review published in Science evaluates whether GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide can preserve human cognitive function. Authored by researchers from the University of Gothenburg and the University of Copenhagen, the analysis synthesizes preclinical learning evidence, mixed observational dementia data, and results from Novo Nordisk’s EVOKE and EVOKE+ clinical trials.
While semaglutide failed to halt clinical progression in established early Alzheimer’s disease, the authors suggest these therapies may safeguard executive function, processing speed, and memory in patients with obesity or type 2 diabetes when administered prior to irreversible neurodegeneration.
Incretin-mimetic therapeutics have restructured metabolic medicine. Peptides engineered to activate glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, such as semaglutide and tirzepatide, produce substantial reductions in hemoglobin A1c and body weight. Beyond peripheral metabolic organs, these peptides alter central appetite networks, reward circuits, and neuroinflammatory pathways.
Because metabolic syndrome, midlife obesity, and type 2 diabetes independently double the lifetime risk of developing vascular dementia and Alzheimer’s disease, whether these medications exert neuroprotective actions has become a core research question.
Source: Neuroscience News — Read the full article on the original site ↗